0000904454-13-000301.txt : 20130219 0000904454-13-000301.hdr.sgml : 20130219 20130215180550 ACCESSION NUMBER: 0000904454-13-000301 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130219 DATE AS OF CHANGE: 20130215 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-86436 FILM NUMBER: 13620976 BUSINESS ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 1-800-849-7894 MAIL ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Technology Partners Fund VIII LP CENTRAL INDEX KEY: 0001409507 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 550 University Avenue CITY: Palo Alto STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 289-9000 MAIL ADDRESS: STREET 1: 550 University Avenue CITY: Palo Alto STATE: CA ZIP: 94301 SC 13G 1 s13g_021513-tonixpharmhold.htm SCHEDULE 13G FOR TONIX PHARMACEUTICALS HOLDING CORP BY TEHCNOLOGY PARTNERS FUND VIII s13g_021513-tonixpharmhold.htm

 
 
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G
 
 
Under the Securities Exchange Act of 1934
(Amendment No.   )*
 
 
 
TONIX PHARMACEUTICALS HOLDING CORP.
(Name of Issuer)
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
890260102
(CUSIP Number)
 
Sheila Mutter
Technology Partners
100 Shoreline Hwy, Suite 282-B
Mill Valley, CA 94941
415-332-9999
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
December 21, 2012
(Date of Event which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
 
  Rule 13d-1(b)
X  Rule 13d-1(c)
  Rule 13d-1(d)
 
 
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
 
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 
 
 


CUSIP No. 890260102
  
13G
  
Page 2 of 7 Pages



1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
TECHNOLOGY PARTNERS FUND VIII, LP
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
(b)    X    (1)
 
3.
SEC USE ONLY
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CALIFORNIA, UNITED STATES OF AMERICA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
 SOLE VOTING POWER
 
0 SHARES
 
6.
 SHARED VOTING POWER
 
4,515,266    (2)
 
7.
 SOLE DISPOSITIVE POWER
 
0 SHARES
 
8.
 SHARED DISPOSITIVE POWER
 
4,515,266
 
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
4,515,266
 
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.99%    (3)
 
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
PN
 

(1)  
This Schedule 13G is filed by Technology Partners Fund VIII, LP, together with its general partner, TP Management VIII, LLC, collectively the “Reporting Persons.”  The Reporting Persons expressly disclaim status as a “Group” for purposes of this Schedule 13G.
 
(2)  
TP Management VIII, LLC owns no securities of the Issuer directly.  TP Management VIII, LLC serves as the general partner of Technology Partners Fund VIII, LP.  The information with respect to ownership of Common Stock by the Reporting Persons is provided as of January 21, 2013.  The 4,515,266 shares of Common Stock reported include 2,015,266 shares of Common Stock underlying warrants.
 
  (3) 
This percentage is calculated based upon a total of 43,182,599 shares of Common Stock issued and outstanding as of January 21, 2013, as set forth in a Statement of Beneficial Ownership provided by the Issuer to the Reporting Persons in the Directors & Officers Questionnaire dated January 21, 2013.

 
 
 


 
CUSIP No. 890260102
  
13G
  
Page 3 of 7 Pages

1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
TP MANAGEMENT VIII, LLC
 
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
(b)    X    (1)
 
3.
SEC USE ONLY
 
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CALIFORNIA, UNITED STATES OF AMERICA
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
 SOLE VOTING POWER
 
0 SHARES
 
6.
 SHARED VOTING POWER
 
4,515,266    (2)
 
7.
 SOLE DISPOSITIVE POWER
 
0 SHARES
 
8.
 SHARED DISPOSITIVE POWER
 
4,515,266
 
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
4,515,266
 
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
9.99%    (3)
 
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
PN
 

(1)  
This Schedule 13G is filed by Technology Partners Fund VIII, LP, together with its general partner, TP Management VIII, LLC, collectively the “Reporting Persons.”  The Reporting Persons expressly disclaim status as a “Group” for purposes of this Schedule 13G.
 
(2)  
TP Management VIII, LLC owns no securities of the Issuer directly.  TP Management VIII, LLC serves as the general partner of Technology Partners Fund VIII, LP.  The information with respect to ownership of Common Stock by the Reporting Persons is provided as of January 21, 2013.  The 4,515,266 shares of Common Stock reported include 2,015,266 shares of Common Stock underlying warrants.
 
  (3) 
This percentage is calculated based upon a total of 43,182,599 shares of Common Stock issued and outstanding as of January 21, 2013, as set forth in a Statement of Beneficial Ownership provided by the Issuer to the Reporting Persons in the Directors & Officers Questionnaire dated January 21, 2013.

 
 
 


         
CUSIP No. 890260102
  
13G
  
Page 4 of 7 Pages

Item 1.
 
 
(a)
Name of Issuer
TONIX PHARMACEUTICALS HOLDING CORP.
     
 
(b)
Address of Issuer’s Principal Executive Offices
509 MADISON AVENUE, SUITE 306, NEW YORK, NY 10022
     
 
Item 2.
 
 
(a)
Name of Person Filing
TECHNOLOGY PARTNERS FUND VIII, LP
TP MANAGEMENT VIII, LLC
     
 
(b)
Address of the Principal Office or, if none, residence
c/o TECHNOLOGY PARTNERS
550 UNIVERSITY AVENUE, PALO ALTO, CA 94301
     
 
(c)
Citizenship
CALIFORNIA – UNITED STATES OF AMERICA
     
 
(d)
Title of Class of Securities
COMMON STOCK
     
 
(e)
CUSIP Number
890260102
 
Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:    NOT APPLICABLE
 
 
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
 
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
 
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
 
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
 
(e)
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
 
(f)
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
 
(g)
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
 
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
 
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
 
(j)
Group, in accordance with §240.13d-1(b)(1)(ii)(J).

CUSIP No. 890260102
  
13G
  
Page 5 of 7 Pages

 

 
Item 4.  Ownership.
 
 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
 
         
 
(a)
  
Amount beneficially owned:  4,515,266
         
 
(b)
  
Percent of class:  9.99%
         
 
(c)
  
Number of shares as to which the person has:  
         
     
(i)
Sole power to vote or to direct the vote …  0
         
     
(ii)
Shared power to vote or to direct the vote …   4,515,266
         
     
(iii)
Sole power to dispose or to direct the disposition of …   0
         
     
(iv)
Shared power to dispose or to direct the disposition of …   4,515,266
         
 
Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
 
 
Item 5.  Ownership of Five Percent or Less of a Class.
 
 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following     .
 
 
Instruction. Dissolution of a group requires a response to this item.
 
 
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
 
 
NOT APPLICABLE
 
 
 
 
 
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
 
 
NOT APPLICABLE
 
 
 
 
 
Item 8.  Identification and Classification of Members of the Group.
 
 
NOT APLICABLE
 
 

 
CUSIP No. 890260102
  
13G
  
Page 6 of 7 Pages
 
 

 
Item 9.  Notice of Dissolution of Group.
 
 
NOT APPLICABLE
 
 
 
 
 
Item 10.  Certification.
 
The following certification is included as this statement is filed pursuant to §240.13d-1(c):


By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 

 
Dated:
February 13, 2013
 
TECHNOLOGY PARTNERS FUND VIII, LP
By:
TP Management VIII, LLC
Its:
General Partner
 
By:
 
 /s/ Sheila Mutter
 
Sheila Mutter
 
Managing Member
 

 
TP MANAGEMENT VIII, LLC
 
By:
 
 /s/ Sheila Mutter
 
Sheila Mutter
 
Managing Member



Exhibit:

A – Joint Filing Agreement

 
 
 


 
CUSIP No. 890260102
  
13G
  
Page 7 of 7 Pages


EXHIBIT A

JOINT FILING AGREEMENT


Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13G relating to the Common Stock of Tonix Pharmaceuticals Holding Corp. to which this Agreement is attached as an Exhibit, and any amendments thereto, is and will be filed with the Securities and Exchange Commission jointly on behalf of each of them.



Dated:
February 13, 2013
 
TECHNOLOGY PARTNERS FUND VIII, LP
By:
TP Management VIII, LLC
Its:
General Partner
 
By:
 
 /s/ Sheila Mutter
 
Sheila Mutter
 
Managing Member


TP MANAGEMENT VIII, LLC
 
By:
 
 /s/ Sheila Mutter
 
Sheila Mutter
 
Managing Member